Literature DB >> 10985328

Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease.

A Gori1, M C Rossi, G Marchetti, D Trabattoni, C Molteni, M Cogliati, A Bandera, M Clerici, F Franzetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10985328     DOI： 10.1097/00002030-200008180-00026

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

1.  Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre.

Authors:  M Gitman; J Vu; T Nguyen; C Chen; C Rotstein
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

Review 2.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma.

Authors:  Jae-Sook Ahn; Sung Yoon Rew; Deok-Hwan Yang; Sung-Hoon Jung; Seung-Ji Kang; Mi-Young Kim; Seung-Shin Lee; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2013-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.